BridgeMD
Tests treatment safety and results for Advanced Cancer
Official title A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors
ClinicalTrials.gov ID: NCT07269145
What this study is testing
What is TQB3122 Capsules?
TQB3122 Capsules is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for advanced cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is the first-in-human clinical study of TQB3122, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3122 in advanced solid tumors, and to preliminarily explore its efficacy in solid tumors.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- The subject voluntarily participates in this study, signs the informed consent form, and has good compliance;
- Gender is not restricted; age (calculated as of the date of signing the informed consent form): 18-75 years old;
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0-1; expected survival period ≥ 3 months;
- Patients with histologically or cytologically confirmed advanced malignant solid tumors, including but not limited to epithelial ovarian cancer...
- Advanced solid tumors that have failed standard treatment (disease progression or intolerance) or for which there is no standard treatment plan;
You likely can't join if
- History of other malignant tumors within 3 years prior to the first administration of the study drug;
- Failure to recover from toxicity and/or complications of previous interventions to CTCAE ≤ Grade 1;
- Risk of bleeding;
- Arterial thrombotic events occurring within 6 months prior to the first administration;
- Suffering from ≥ Grade 2 myocardial ischemia or myocardial infarction, supraventricular or ventricular arrhythmias, and ≥ Grade 2 congestive heart...
- History of psychotropic substance abuse with inability to abstain, or presence of mental disorders; patients with epilepsy requiring treatment; or...
See the full eligibility criteria
- The subject voluntarily participates in this study, signs the informed consent form, and has good compliance;
- Gender is not restricted; age (calculated as of the date of signing the informed consent form): 18-75 years old;
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0-1; expected survival period ≥ 3 months;
- Patients with histologically or cytologically confirmed advanced malignant solid tumors, including but not limited to epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, breast cancer, prostate...
- Advanced solid tumors that have failed standard treatment (disease progression or intolerance) or for which there is no standard treatment plan;
- For Phase Ib (dose expansion stage), except for patients receiving maintenance treatment for ovarian cancer/fallopian tube cancer/primary peritoneal cancer, other patients are required to have target lesions meeting the...
- Good function of major organs;
- Women of childbearing age must agree to use effective contraceptive measures during the study and within 6 months after the end of the study; serum or urine pregnancy test must be negative within 7 days before...
- History of other malignant tumors within 3 years prior to the first administration of the study drug;
- Failure to recover from toxicity and/or complications of previous interventions to CTCAE ≤ Grade 1;
- Risk of bleeding;
- Arterial thrombotic events occurring within 6 months prior to the first administration;
- Suffering from ≥ Grade 2 myocardial ischemia or myocardial infarction, supraventricular or ventricular arrhythmias, and ≥ Grade 2 congestive heart failure; poorly controlled blood pressure;
- History of psychotropic substance abuse with inability to abstain, or presence of mental disorders; patients with epilepsy requiring treatment; or patients with severe mental or neurological diseases;
- Active or uncontrolled severe infections;
- Active syphilis; HIV infection or other immunodeficiency diseases; active hepatitis B or active hepatitis C;
- Complicated with moderate to severe pulmonary diseases that significantly affect respiratory function;
- Patients with active autoimmune diseases requiring systemic treatment (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants);
- Receipt of systemic treatment with prednisone \> 10 mg/day or equivalent drugs, or any other form of immunosuppressive therapy within 2 weeks prior to administration;
- History of organ transplantation (except corneal transplantation), allogeneic or autologous hematopoietic stem cell transplantation;
- Poorly controlled diabetes mellitus;
- Patients with leptomeningeal (including arachnoid and pia mater) metastases;
- Known central nervous system (CNS) involvement;
- Presence of massive serous cavity (pleural, peritoneal, or pericardial) effusions requiring repeated drainage to relieve clinical symptoms, or receipt of therapeutic serous cavity effusion drainage within 2 weeks prior...
- Current intestinal obstruction;
- Known allergy to the components of the study drug;
- Receipt of anti-tumor treatments such as radiotherapy, chemotherapy, targeted therapy, or immunotherapy within 4 weeks prior to the first administration;
- Receipt of Chinese patent medicines explicitly indicated for anti-tumor use in their drug labels approved by National Medical Products Administration (NMPA) within 2 weeks prior to the first administration;
- According to the investigator's judgment, people with concomitant diseases that severely endanger their safety or affect the completion of the study, or those deemed unsuitable for enrollment for other reasons.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
- Fuzhou, Fujian, China
- Meizhou, Guangdong, China
- Shanghai, Shanghai Municipality, China
- Chengdu, Sichuan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China; Fuzhou, Fujian, China; Meizhou, Guangdong, China; Shanghai, Shanghai Municipality, China; Chengdu, Sichuan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.